SYRE vs ARRY vs PRTA vs RCUS vs JNJ

For growth investors, Array Technologies, Inc.

(ARRY) is the stronger pick with 40. 2% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Johnson & Johnson (JNJ) offers the better valuation at 38. 4x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Spyre Therapeutics, Inc. (SYRE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Array Technologies, Inc.

is actually cheaper at 11. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +46.

1%, compared to -67. 7% for Array Technologies, Inc. (ARRY). Over 10 years, the gap is even starker: JNJ returned +132. 3% versus ARRY's -77. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Array Technologies, Inc. 's 2. 32β — meaning ARRY is approximately 3966% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Prothena Corporation plc (PRTA) carries a lower debt/equity ratio of 5% versus 3% for Array Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Array Technologies, Inc.

(ARRY) is pulling ahead at 40. 2% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Array Technologies, Inc. grew EPS 62. 6% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Array Technologies, Inc.

(ARRY) trades at 11. 7x forward P/E versus 42. 7x for Prothena Corporation plc — 30. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 80. 4% to $19. 00.

In this comparison, JNJ (2.

2% yield) pays a dividend. SYRE, ARRY, PRTA, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Array Technologies, Inc. (ARRY) carries a higher beta of 2. 32 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JNJ: +132. 3%, ARRY: -77. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SYRE (Healthcare) and ARRY (Energy) and PRTA (Healthcare) and RCUS (Healthcare) and JNJ (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SYRE is a mid-cap quality compounder stock; ARRY is a small-cap high-growth stock; PRTA is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock. JNJ pays a dividend while SYRE, ARRY, PRTA, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.